We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.39%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
+$177M
Cap. Flow
-$53.9M
Cap. Flow %
-1.89%
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
42
Reduced
44
Closed
16

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$46M
2
DHR icon
Danaher
DHR
+$34.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$22.3M
5
DXCM icon
DexCom
DXCM
+$20M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$44.2M
2
MRK icon
Merck
MRK
+$39.7M
3
PFE icon
Pfizer
PFE
+$39.7M
4
ABBV icon
AbbVie
ABBV
+$24.5M
5
CNC icon
Centene
CNC
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.34%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
126
Aurinia Pharmaceuticals
AUPH
$1.95B
$4.16M 0.15%
300,611
– –
AMRN
127
Amarin Corp
AMRN
$302M
$4.15M 0.15%
42,479
– –
PRAX icon
128
Praxis Precision Medicines
PRAX
$8.9B
$4.13M 0.15%
+5,000
New +$2.92M
AXNX
129
DELISTED
Axonics, Inc. Common Stock
AXNX
$4.03M 0.14%
80,760
+61,360
+316% +$2.88M
SNY icon
130
Sanofi
SNY
$103B
$3.96M 0.14%
81,554
-300,366
-79% -$14.8M
ARDX icon
131
Ardelyx
ARDX
$1.21B
$3.93M 0.14%
607,698
– –
TAK icon
132
Takeda Pharmaceutical
TAK
$53.4B
$3.83M 0.13%
210,146
– –
ENDP
133
DELISTED
Endo International plc
ENDP
$3.82M 0.13%
531,570
– –
YMAB
134
DELISTED
Y-mAbs Therapeutics
YMAB
$3.79M 0.13%
76,548
– –
PVLA
135
Palvella Therapeutics
PVLA
$2.22B
$3.62M 0.13%
18,116
– –
ABMD
136
DELISTED
Abiomed Inc
ABMD
$3.5M 0.12%
10,812
-1,400
-11% -$387K
DCPH
137
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.5M 0.12%
61,370
– –
ALKS icon
138
Alkermes
ALKS
$8.32B
$3.39M 0.12%
169,930
– –
THC icon
139
Tenet Healthcare
THC
$21.1B
$3.3M 0.12%
82,736
-14,000
-14% -$452K
INSM icon
140
Insmed
INSM
$21.5B
$3.27M 0.12%
98,387
– –
PHG icon
141
Philips
PHG
$26B
$3.08M 0.11%
70,195
– –
HR
142
DELISTED
Healthcare Realty Trust Incorporated
HR
$3.08M 0.11%
104,024
– –
NKTR icon
143
Nektar Therapeutics
NKTR
$2.47B
$3.07M 0.11%
12,029
-5,510
-31% -$1.42M
KDMN
144
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.96M 0.1%
714,008
– –
HRTX icon
145
Heron Therapeutics
HRTX
$95.5M
$2.78M 0.1%
131,183
– –
MLTX icon
146
MoonLake Immunotherapeutics
MLTX
$1.49B
$2.71M 0.1%
+250,000
New +$2.65M
ZYME icon
147
Zymeworks
ZYME
$1.73B
$2.64M 0.09%
55,938
– –
EIDX
148
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$2.63M 0.09%
20,000
– –
MEDP icon
149
Medpace
MEDP
$16.4B
$2.63M 0.09%
18,871
– –
AXSM icon
150
Axsome Therapeutics
AXSM
$11B
$2.57M 0.09%
31,591
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Tekla Capital Management held 216 positions worth $2.85B, up 6.6% from $2.67B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Tekla Capital Management's Q4 2020 filing shows 12 new, 42 increased, 44 reduced and 16 closed positions. Its largest new stake was Teladoc Health: 56,520 shares worth $11.3M. The largest sale was Amgen, an estimated $44.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2020 buy was Teladoc Health: 56,520 shares worth $11.3M.
  • Tekla Capital Management added most to Thermo Fisher Scientific in Q4 2020, an estimated $46M increase.
  • Tekla Capital Management's biggest Q4 2020 reduction was Amgen, cutting an estimated $44.2M.
  • Tekla Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $19M.
  • Tekla Capital Management's ten largest holdings make up 28% of its $2.85B portfolio in Q4 2020.
  • Tekla Capital Management opened 12 new positions and closed 16 in Q4 2020.
  • Tekla Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.